Search results for " plasmids"
Article
Top Challenges to Overcome When Developing AAV Processes: Part 1 of 2
AAVprocessdevelopment
Click here to view more Industry Leader Q&As >>
In the first of a two-part series, Anki Magnusson, Staff Research Engineer, Protein and Viral Producti…
Article
Cell-free Expression Systems Pose Cell Culture Alternative
Cell-free expression is promising in preclinical applications, but still presents challenges to scale up for commercial production.
Feliza Mirasol
Among the challenges in upstrea…
Article
Single-Use Technologies Prove Effective for Viral Vector Process Development
The benefits of single-use technologies for upstream viral-vector processes clearly outweigh their disadvantages.
Cynthia A. Challener
Upstream viral-vector processes can have sig…
Article
Innovative Chromatography Resins Can Improve Purity and Quality
“For instance, when it comes to the purification of truly large molecules, such as large proteins, viral vectors, or plasmids, these molecules may not be able to enter the pores of the beads, resultin…
Article
Genetic Vaccine Platforms Demonstrate Their Potential
In a pandemic, genetic vaccines offer several advantages over traditional approaches.
By Cynthia A. Challener
For a vaccine to be effective, the components of the disease o…
Article
Process Development: 2020 Reflections and 2021 Possibilities
The challenges posed by the COVID-19 pandemic in 2020 brought about many unprecedented lessons and promising developments in the biopharmaceutical industry. Last year in particular reenforced the ne…
Article
Virus-like Particles as Therapeutic Moieties of the Future
Analytical and functional characterization of virus-like particles enables process reproducibility and product consistency.
By Ramesh Kumar, Manidipa Banerjee, Anurag S. Rathore
Virus-like…
Article
Technology Innovations Improve Process Chromatography Performance
Convective flow membrane chromatography and monoliths addressed the previous purification challenges with diffusive matrices for large molecules, such as viruses (> 100 nm), plasmids, or even large pr…
Article
Can Vaccine Development Be Safely Accelerated?
The plasmids are then produced in large quantities using bacteria. The overall development and approval timeline is thereby significantly reduced.
Inovio began animal testing of INO-4800, its C…
Article
Mapping a Route for Cell and Gene Therapy Process Development
He points in particular to the avoidance of the use of plasmids and the development of packaging/stable cell lines as current key issues.
Reducing manufacturing costs, as well as development of…